FDA
-
-
-
-
-
-
-
Larimar Therapeutics to host investor event on June 29
-
-
-
-
-
-
-
Guggenheim on Larimar (LRMR): 'With multiple near-term catalysts on the horizon, we see substantial upside potential'
-
-
-
-
-
-
-
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Larimar Therapeutics (LRMR)
-
-
-
-
-
-
-
Larimar Therapeutics (LRMR) Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
-
-
-
-
-
-
-
Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR)
-
-
-
-
-
-
-
Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR)
-
330,535 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

